Liability on the Frontline - Part 4: Fighting COVID-19 with genomics

Liability on the Frontline - Part 4: Fighting COVID-19 with genomics

Published on 14/01/2021
Liability on the Frontline - Part 4: Fighting COVID-19 with genomics From fast-tracked clinical trials to emergency medical devices and telehealth innovations, the Life Sciences sector is providing solutions to Covid-19. This series of reports explores what risks organisations are entering into as they ride to the world’s rescue and how they can protect themselves 

Liability on the Frontline - Part 4: Fighting COVID-19 with genomics


Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare.

When the Black Death seized the world in the Middle Ages, the words did not exist to describe what was killing millions of people. When COVID-19 was identified as a pandemic risk in the first few days of 2020, Chinese scientists peered deep inside the virus and sequenced its genome, reading the genetic ‘instruction manual’ for how it is built. That genome sequence was shared with the international community and researchers quickly brought genomics – the study of an organism’s full set of genes and how they function – to bear on the virus.

Read the full report here: https://www.chubb.com/uk-en/business/life-science-in-the-era-of-pandemics.html​
 

Our Valued Sponsors & Partners